BTG's Louise Makin On Joining IO Agents And Localized Intervention
Executive Summary
BTG's CEO says combining novel immuno-oncology therapies with image-guided, minimally invasive therapies could deliver treatments where needed while lowering overall treatment costs.
You may also be interested in...
BTG Has The Firepower For Its Next Steps In Interventional Med
UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.
BTG Shoots For $1 Billion Revenue Stars In On-Going Transformation
The specialist health care company is building a multi-asset interventional medicines business that it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.